Recent Announcements
PhotoPharmics Expands Enrollment Beyond 300 in Groundbreaking Trial to Show Improvement Beyond Current Therapies
New clinical sites open in Illinois, Florida, and Arizona; trial remains open...
A Guide to Understanding and Managing Sleep Problems in Parkinson’s Disease
The Unseen Struggle of Parkinson's at Night When we think of Parkinson's...
Innovations in Parkinson’s Treatment: Exploring Light Therapy and Beyond – Part-2
Introduction Welcome back to our exploration of groundbreaking advancements in...
Parkinson’s Treatment: Light Therapy and Beyond-Part 1
Innovations in Parkinson's Treatment: Exploring Light Therapy and Beyond...
PhotoPharmics Strengthens Executive Team with Appointments of Samantha John and Greg Schneider
Veteran leaders join to accelerate commercialization and market access...
Subtle Signs of Parkinson’s: Before The Visible Tremors
Introduction Parkinson's Disease (PD) has long been associated with its...
PhotoPharmics Closes Oversubscribed $6 Million Series B Extension to Advance FDA Breakthrough Parkinson’s Device
Original Press Release Funding supports key milestones as the Pivotal, Phase 3...
PhotoPharmics Reaches 200 Participants in Landmark Light for PD Clinical Trial
Two-thirds enrolled in one of the largest remote Parkinson’s trials—redefining...
10 Ways to Manage Your Parkinson’s Symptoms
Introduction Living with Parkinson's disease presents a unique set of...
Available Diagnosis and Treatment for Parkinson’s
Introduction Parkinson’s is one of the most common neurodegenerative...
Updates
PhotoPharmics Announces Leadership Transition in Clinical & Scientific Advisory Board
PhotoPharmics, a pioneer in specialized phototherapy for neurodegenerative...
PhotoPharmics to Present Patient Interest Findings from Groundbreaking Remote Parkinson’s Trial at PSG Annual Meeting
Presentation to Highlight Feasibility and Interest in Decentralized Home-Based...
PhotoPharmics Announces First Subject Completes FDA Pivotal Clinical Trial for the Celeste Device in Parkinson’s
Milestone Marks Significant Progress in Establishing Non-invasive Phototherapy...
PhotoPharmics Welcomes Three Renowned Experts to Its Clinical & Scientific Advisory Board
Company Strengthens Its Leadership in Neurodegenerative Disease Research with...
PhotoPharmics Enrolls First 100 Participants in Groundbreaking Parkinson’s Disease Trial
Innovative Study Advances to Critical Phase in Evaluating Light Therapy for...
PhotoPharmics Enrolls First 25 Patients in Pivotal Parkinson’s Disease Study to Improve Symptoms Beyond the Current Standard of Care
PhotoPharmics Enrolls First 25 Patients in Pivotal Parkinson’s Disease Study...
Largest Phototherapy Trial for Parkinson’s Disease
Largest Phototherapy Trial for Parkinson’s Disease Pivotal Trial Aims to...
Innovative Research, Inclusive Trials, and New Funding Drives Hope for People with Parkinson’s Disease
PhotoPharmics Secures $16 Million Investment Led by Kickstart to Fund Pivotal...
Celeste® Light for PD Trial to be Presented at World Parkinson’s Congress
Celeste® Light for PD Trial to be Presented at World Parkinson’s Congress...